by Manisha Kashyap, PhD

Hepatocellular carcinoma (HCC) is among the most challenging liver malignancies, ranking as the sixth most common cancer globally and the third leading cause of cancer-related deaths. Late diagnosis, rapid progression, and limited therapeutic options significantly contribute to the high mortality associated with HCC. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors targeting PD-L1, have revolutionized cancer treatment. Nevertheless, resistance to these treatments remains a significant barrier. Addressing this challenge, researchers at the Second Affiliated Hospital of Jiaxing University in China have provided compelling new insights into the role of ENTPD8 (ectonucleoside triphosphate diphosphohydrolase 8) in enhancing anti-PD-L1 therapy effectiveness. The study, published January 16, 2025 in iScience, under the title “ENTPD8 Overexpression Enhances Anti-PD-L1 Therapy in Hepatocellular Carcinoma via miR-214-5p Inhibition” identifies ENTPD8 as a novel and promising therapeutic target capable of boosting immunotherapy outcomes in HCC by regulating a microRNA (miR-214-5p).
